A 38-year-old woman with recurrent syncope and palpitations is found to have a prolonged QT interval on ECG (QTc 520 ms). She reports a family history of sudden cardiac death. To determine the underlying mechanism of impaired cardiac output regulation and assess risk of malignant arrhythmias, which investigation is most appropriate?

Explanation

## Investigation of Choice for Long QT Syndrome Risk Stratification ### Clinical Context This patient presents with: - Recurrent syncope and palpitations (arrhythmia symptoms) - Prolonged QTc interval (≥500 ms is abnormal; >520 ms is significant) - Family history of sudden cardiac death - Classic presentation of **Long QT Syndrome (LQTS)** The goal is to identify the underlying genetic etiology and stratify arrhythmia risk to guide therapy and family screening. ### Why Genetic Testing is the Answer **Key Point:** Genetic testing for ion channel mutations is the investigation of choice for confirming the diagnosis of inherited Long QT Syndrome and determining the specific subtype, which guides risk stratification and therapy. **High-Yield:** Long QT Syndrome is a channelopathy with multiple genetic subtypes: | Gene | Protein | Subtype | Clinical Features | Trigger | |---|---|---|---|---| | **KCNQ1** | K~v~7.1 (slow K^+^ current) | LQT1 | Most common (45%); syncope with exercise/emotion | Emotional stress, exercise | | **KCNH2** | hERG (rapid K^+^ current) | LQT2 | Syncope with auditory triggers (alarm, phone) | Auditory stimuli | | **SCN5A** | Na~v~1.5 (fast Na^+^ current) | LQT3 | Syncope at rest/sleep; longer QT; highest mortality | Rest, sleep | | **KCNE1, KCNE2** | β-subunits | LQT5, LQT6 | Rare; variable phenotype | Variable | **Clinical Pearl:** Identifying the specific LQTS subtype is crucial because: - **LQT1:** β-blockers are highly effective (>90% risk reduction) - **LQT2:** β-blockers + ICD for high-risk patients; avoid triggers - **LQT3:** Sodium channel blockers (mexiletine, flecainide); ICD for high-risk ### Pathophysiology of Impaired Cardiac Output Regulation ```mermaid flowchart TD A[Ion Channel Mutation]:::outcome --> B[Abnormal repolarization current]:::outcome B --> C[Prolonged action potential duration]:::outcome C --> D[Prolonged QT interval on ECG]:::outcome D --> E[Early afterdepolarizations]:::outcome E --> F[Triggered activity]:::outcome F --> G[Torsades de Pointes]:::urgent G --> H[Syncope or Sudden Cardiac Death]:::urgent I[Genetic Testing]:::action --> J{Mutation identified?}:::decision J -->|Yes| K[Confirm LQTS subtype]:::outcome J -->|No| L[Consider acquired LQTS or other channelopathy]:::outcome K --> M[Risk stratification + Family screening]:::action ``` ### Why Other Investigations Are Secondary **Warning:** Do not confuse diagnostic testing with risk stratification testing. Genetic testing diagnoses the condition; other tests assess arrhythmia burden but do not identify the underlying mechanism. | Investigation | Role | Limitation | |---|---|---| | **Exercise stress test** | Provokes arrhythmias in LQT1 (exercise-triggered); useful for phenotyping | Does not identify genetic cause; may precipitate dangerous arrhythmias | | **Holter monitor** | Detects spontaneous arrhythmias (Torsades de Pointes) and QT prolongation patterns | Passive monitoring; does not diagnose genetic etiology; low sensitivity in asymptomatic periods | | **Echocardiography** | Rules out structural heart disease (dilated cardiomyopathy, HCM) | LQTS is a functional disorder; echo is usually normal; does not address genetic cause | **Mnemonic:** **LQTS Genetics = KCNQ, KCNH, SCN** — Remember the three major genes: - **K**CNQ1 (K channel) → LQT1 - **K**CNH2 (hERG) → LQT2 - **S**CN5A (Na channel) → LQT3 ### Clinical Management Implications **High-Yield:** Once genetic testing confirms LQTS and identifies the subtype: 1. **LQT1:** Start β-blockers (propranolol, nadolol); avoid strenuous exercise 2. **LQT2:** β-blockers + ICD for high-risk (QTc >500 ms, recurrent syncope, family history of SCD) 3. **LQT3:** Sodium channel blockers (mexiletine, flecainide) + ICD for high-risk 4. **Family screening:** Genetic counseling and testing for first-degree relatives 5. **Avoid QT-prolonging drugs:** Antiarrhythmics, antipsychotics, antibiotics (fluoroquinolones, macrolides), antihistamines [cite:Harrison 21e Ch 226]